​

Rhythm Pharmaceuticals (RYTM) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Rhythm Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$189.76M

Latest Revenue (Q)

$60.11M

Main Segment (Y)

Product

Main Geography (Y)

Non-US

Rhythm Pharmaceuticals Revenue by Period

Rhythm Pharmaceuticals Revenue by Year

DateRevenueChange
2025-12-31$189.76M45.83%
2024-12-31$130.13M68.06%
2023-12-31$77.43M227.56%
2022-12-31$23.64M649.46%
2021-12-31$3.15M100.00%
2020-12-31-100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31-100.00%
2016-12-31-100.00%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31-100.00%
2012-12-31--

Rhythm Pharmaceuticals generated $189.76M in revenue during NA 2025, up 45.83% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Rhythm Pharmaceuticals Revenue by Quarter

DateRevenueChange
2026-03-31$60.11M4.99%
2025-12-31$57.25M11.61%
2025-09-30$51.30M5.76%
2025-06-30$48.50M48.31%
2025-03-31$32.70M-21.82%
2024-12-31$41.83M25.80%
2024-09-30$33.25M14.35%
2024-06-30$29.08M11.98%
2024-03-31$25.97M7.15%
2023-12-31$24.23M7.69%
2023-09-30$22.50M17.08%
2023-06-30$19.22M67.59%
2023-03-31$11.47M30.48%
2022-12-31$8.79M105.18%
2022-09-30$4.28M-52.75%
2022-06-30$9.07M505.21%
2022-03-31$1.50M-17.56%
2021-12-31$1.82M76.75%
2021-09-30$1.03M275.18%
2021-06-30$274.00K682.86%
2021-03-31$35.00K100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31-100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2017-03-31-100.00%
2016-12-31-100.00%
2016-09-30--

Rhythm Pharmaceuticals generated $60.11M in revenue during Q1 2026, up 4.99% compared to the previous quarter, and up 143.71% compared to the same period a year ago.

Rhythm Pharmaceuticals Revenue Breakdown

Rhythm Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24Dec 23Dec 22
Product$194.77M$130.13M$77.43M-
License$-5.01M---
Product revenue---$16.88M
License revenue---$6.75M

Rhythm Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 25: Product (102.64%), and License (-2.64%).

Quarterly Revenue by Product

Product/ServiceMar 26Dec 25Sep 25Jun 25Mar 25Dec 24Mar 24Jun 23Dec 22Sep 22Jun 22
Product$60.11M$57.25M$51.30M$48.50M$37.72M$104.16M$25.97M----
License-$10.03M$-5.01M$-5.01M$-5.01M------
Product revenue-------$19.22M$8.79M$4.28M$2.31M
License revenue----------$6.75M

Rhythm Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Mar 26: Product (100.00%).

Rhythm Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 25Dec 24Dec 23
Non-US$61.22M$34.02M-
UNITED STATES-$96.11M$62.42M
Other Countries--$8.93M
GERMANY--$6.08M

Rhythm Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 25: Non-US (100.00%).

Quarterly Revenue by Country

CountryMar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24
Non-US$23.22M$18.27M$13.08M$16.52M$13.35M--
UNITED STATES-----$72.81M$23.30M
GERMANY------$3.62M
Other Countries------$6.33M

Rhythm Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Mar 26: Non-US (100.00%).

Rhythm Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
KNSAKiniksa Pharmaceuticals$677.56M$214.27M
ARVNArvinas$262.60M$15.60M
RYTMRhythm Pharmaceuticals$189.76M$60.11M
STOKStoke Therapeutics$184.42M$6.23M
SNDXSyndax Pharmaceuticals$172.35M$64.86M
VRDNViridian Therapeutics$70.85M$141.00K
MGTXMeiraGTx$33.28M$293.00K
RNAAtrium Therapeutics$18.75M$12.47M
QUREuniQure$16.10M$3.56M
RLAYRelay Therapeutics$15.36M$3.00M
CGEMCullinan Therapeutics--
AKROAkero Therapeutics--
SLDBSolid Biosciences--
BDTXBlack Diamond Therapeutics--
PTGXProtagonist Therapeutics--
VTYXVentyx Biosciences--
NUVLNuvalent--
RCKTRocket Pharmaceuticals--
RVMDRevolution Medicines--
ACLXArcellx-$7.55M
PLRXPliant Therapeutics--

RYTM Revenue FAQ

What is Rhythm Pharmaceuticals’s yearly revenue?

Rhythm Pharmaceuticals's yearly revenue for 2025 was $189.76M, representing an increase of 45.83% compared to 2024. The company's yearly revenue for 2024 was $130.13M, representing an increase of 68.06% compared to 2023. RYTM's yearly revenue for 2023 was $77.43M, representing an increase of 227.56% compared to 2022.

What is Rhythm Pharmaceuticals’s quarterly revenue?

Rhythm Pharmaceuticals's quarterly revenue for Q1 2026 was $60.11M, a 4.99% increase from the previous quarter (Q4 2025), and a 83.81% increase year-over-year (Q1 2025). The company's quarterly revenue for Q4 2025 was $57.25M, a 11.61% increase from the previous quarter (Q3 2025), and a 36.87% increase year-over-year (Q4 2024). RYTM's quarterly revenue for Q3 2025 was $51.3M, a 5.76% increase from the previous quarter (Q2 2025), and a 54.28% increase year-over-year (Q3 2024).

What is Rhythm Pharmaceuticals’s revenue growth rate?

Rhythm Pharmaceuticals's revenue growth rate for the last 3 years (2023-2025) was 145.08%, and for the last 5 years (2021-2025) was 5916.39%.

What are Rhythm Pharmaceuticals’s revenue streams?

Rhythm Pharmaceuticals's revenue streams in c 25 are Product, and License. Product generated $194.77M in revenue, accounting 102.64% of the company's total revenue, up 49.68% year-over-year. License generated $-5.014M in revenue, accounting -2.64% of the company's total revenue

What is Rhythm Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Rhythm Pharmaceuticals was Product. This segment made a revenue of $194.77M, representing 102.64% of the company's total revenue.